SCHEDULE: Ameriprise Entities Report Stake in Apnimed

Ameriprise Financial, Inc. and its subsidiaries, Columbia Management Investment Advisers, LLC and Columbia Seligman Technology and Information Fund, have reported beneficial ownership of 18.9% of Apnimed, Inc.'s common stock as of July 31, 2026.

Summary

• Ameriprise Financial, Inc. (AFI), Columbia Management Investment Advisers, LLC (CMIA), and Columbia Seligman Technology and Information Fund (Fund) have filed a Schedule 13G.
• The filing indicates that as of July 31, 2026, these entities collectively beneficially own 7,476,992 shares of Apnimed, Inc. common stock.
• This represents 18.9% of the class of securities.
• CMIA, as the investment adviser to the Fund and other accounts, may be deemed to beneficially own the shares held by the Fund.
• AFI, as the parent holding company of CMIA, may also be deemed to beneficially own these shares.
• The Fund itself directly owns 7,198,843 shares, representing 18.2% of the class.
• AFI and CMIA disclaim beneficial ownership of any shares reported on this Schedule.
• No other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein, other than the reporting entities and those for whom CMIA and AFI report beneficial ownership.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes rather than operational or financial performance.

Positives

• Significant institutional ownership reported by established financial entities, which can indicate confidence in the company's long-term prospects.
• The Fund holds a substantial 18.2% stake, suggesting a considerable investment.

Negatives

• The filing does not contain financial performance data, operational updates, or strategic guidance, limiting the assessment of the company's current health.
• The disclaimer of beneficial ownership by AFI and CMIA, while standard, indicates indirect control or influence over the shares held by the Fund.

Risks

• Potential for significant share sales by these large institutional holders could impact the stock price.
• Changes in investment strategy by Ameriprise entities could lead to divestment.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it is a disclosure of beneficial ownership.

Management Comments

• Each of AFI and CMIA, and the subsidiaries identified on the attached Exhibit I, disclaims beneficial ownership of any shares reported on this Schedule.
• To the knowledge of AFI, CMIA and the Fund, no other persons besides AFI, CMIA and the Fund and those persons for whose shares of common stock CMIA and AFI report beneficial ownership have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the securities of the issuer reported herein.
• As of July 31, 2026, only the Fund owned more than 5% of the class of securities reported herein.
• Any remaining shares reported herein by CMIA are held by various other funds or accounts managed by CMIA which each have the right to receive any dividends paid by the issuer and could terminate their respective investment advisory relationship with CMIA and then subsequently direct the use of proceeds from the sale of the common stock owned by such fund or account.
• To CMIA's knowledge, none of these other funds or accounts own more than 5% of the outstanding shares of the issuer as of July 31, 2026.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates a substantial investment by Ameriprise entities in Apnimed, Inc., positioning them as key stakeholders.

Stakeholder Impact

• Shareholders: The significant stake held by institutional investors may influence market perception and trading activity. Any future changes in this stake could impact share price.
• Management: The presence of a large institutional holder like the Fund may lead to increased engagement or scrutiny from the reporting entities.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Monitor future filings from Ameriprise Financial, Inc., Columbia Management Investment Advisers, LLC, and Columbia Seligman Technology and Information Fund for any changes in their beneficial ownership of Apnimed, Inc. stock.

Key Dates

Keywords

Apnimed, Schedule 13G, Beneficial Ownership, Institutional Investor, Ameriprise Financial, Columbia Management, Common Stock